AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals

BERWYN, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today launched its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive digital resource for information on new, pending and upcoming specialty and rare disease drug launches, biosimilars and cell and gene therapies (CGTs). This complimentary quarterly publication provides stakeholders and decision-makers with crucial, timely updates to support the needs of the specialty drug market.

To read more, click here

Read our Privacy Policy to learn more.